Kornimate/medical-research-clean huggingface dataset:
community-based intervention for cervical cancer screening uptake in nepal

Conditions: Cervical Cancer Screening

Summary: this study aims to evaluate the effect of a female community health volunteer (fchv) led community-based educational intervention through home visits increasing cervical cancer screening uptake.

cervical cancer is the major cause of cancer deaths among women in nepal. screening is one of the most effective tools for early diagnosis, prevention, and treatment. however, skilled health professionals and tools available for cervical cancer screening are limited in low and middle-income countries (lmics) including nepal. the world health organization (who) and alliance for cervical cancer prevention (accp) recommends that countries, areas, or institutions seeking to initiate or strengthen cervical cancer screening programs should consider introducing or expanding visual inspection with acetic acid (via) until more appropriate and affordable hpv-based tests become available. 'national guideline for cervical cancer screening and prevention in nepal, 2010' includes via as a screening method for cervical cancer. current studies reveal nepalese women's participation in cervical cancer screening is low. thus, there is a need for appropriate, cost-effective and sustainable interventions to increase via screening uptake at the primary health care level across nepal. the primary objective of this study is to evaluate the effect of a female community health volunteer (fchv) led community-based educational intervention through home visits increasing cervical cancer screening uptake. the primary outcome of the study is to increase the cervical cancer-screening uptake in the intervention group. this will be the first community-based cluster-randomized trial designed to mobilize fchvs for increasing cervical cancer screening uptake in nepal.

Eligibility criteria:
inclusion criteria: * all women of age group 30-60 years who were recruited in the cobin wave i survey exclusion criteria: * women who are not able to give consent * severely ill, * pregnant or less than 6 weeks after delivery, * who is already diagnosed with cervical pre-cancer and cancer * with a history of total hysterectomy * who are reluctant to participate in the study or unable to complete the interview

Keywords: cervical cancer screening community health worker community-based female community health volunteers non-communicable diseases randomized controlled trial nepal
allergic rhinitis with/without asthma: pre- and post-qipian analysis

Conditions: Rhinitis, Allergic; Asthma

Summary: allergic rhinitis and asthma are common respiratory diseases. qipian® is a chinese medicine made from three types of bacteria, used to treat these conditions. this study will retrospectively analyze the effects of adding qipian® to the regular treatment for patients with allergic rhinitis, with or without asthma. patients meeting the allergic rhinitis and its impact on asthma（aria） and global initiative for asthma（gina） diagnostic criteria were divided into two groups: one receiving standard drug treatment, and the other receiving standard treatment plus qipian®. the study will compare clinical symptoms and relevant blood markers before and after treatment to see if adding qipian® leads to better outcomes than the standard treatment alone.this study aims to determine how qipian® benefits patients with rhinitis and asthma and its effect on related serum indicators, helping to explore its role in allergic respiratory diseases.

allergic rhinitis and asthma are common chronic respiratory diseases, with rising prevalence each year. bacterial lysates (bls) are a potential treatment option that has been used for over 100 years. qipian® is a chinese medication containing extracts from three types of bacteria, used to treat chronic respiratory diseases. it effectively alleviates symptoms and improves the immune system. this study will retrospectively analyze the clinical efficacy of adding qipian® to the conventional drug treatment in patients with allergic rhinitis with or without asthma. patients diagnosed with rhinitis and asthma according to aria and gina guidelines were included in the study. they will be divided into two groups based on their treatment regimen: a conventional drug treatment group and a conventional drug plus qipian® treatment group. clinical symptoms and relevant serum markers were collected to assess changes before and after treatment, and to determine whether the addition of qipian® results in more significant improvements compared to the conventional drug treatment group. this will help determine the benefits of qipian® for patients with rhinitis, with or without asthma, in terms of clinical symptoms and serum indicators, and further explore its role in allergic respiratory diseases.

Eligibility criteria:
inclusion criteria: * patients with rhinitis who meet the aria (allergic rhinitis and its impact on asthma) guidelines. * patients with asthma who meet the gina (global initiative for asthma) guidelines. exclusion criteria: * patients undergoing combined dust mite-specific immunotherapy * patients undergoing combined treatment with biologics, including omalizumab, dupilumab, or mepolizumab. * patients undergoing combined treatment with small molecule drugs, including upadacitinib, abrocitinib, baricitinib, and other jak inhibitors. * patients who are unwilling to comply with treatment, are unable to adhere to regular medication schedules, and do not attend follow-up appointments.

Keywords: rhinitis asthma qipian immunoglobulin cytokine
observational registry study: firehawk des for treating coronary artery disease (cad)

Conditions: Coronary Artery Disease

Summary: the study aims to further assess the safety, efficacy and the performance of its delivery system of firehawk rapamycin-eluting stent up to five years.

this is a prospective open-labeled, multi-center, single-arm observational registry study. approximately 1,100 subjects will be enrolled to evaluate the tlf as the primary endpoint at 12-month. also, the study will follow up those subjects up to 5 years as the secondary endpoints.

Eligibility criteria:
inclusion criteria: * age 18-75, male or unpregnant women * evidence of non-symptomatic ischemia, stable or non-stable angina or past mi * native coronary artery target lesion * target lesion length \<=60mm, target lesion vessel diameter 2.25mm-4.0mm * target lesion diameter stenosis\>=70% * for each target lesion, firehawk stent implantation only * understand the study purpose, willing to participate and sign the letter of consent * acceptance of clinical follow-up exclusion criteria: * acute mi within 72 hours * unprotected lm and intervention-required three-vessel lesions * calcified lesion failed in pre-dilation and twisted lesion * bridge vessel lesion * any stent implanted within one year * severe heart failure (hyha\>=iii) or lvef\<40% * renal deficiency, blood creatinine \> 2.0mg/dl * bleeding tendency * allergic to aspirin, clopidogrel, ticlopidine, dye, rapamycin and metal * life expectation \<12 months * history of not achieving study finish * no compliances to the protocol * heart implantation subjects

Keywords: des cad firehawk microport pci
activity at 25% above the ventilation threshold on appetite and food intake in boys

Conditions: Healthy Boys With no Emotional, Behavioral or Learning Problems Within a Normal Body Weight

Summary: the investigators hypothesize exercise increases short term appetite and food intake, and interferes with satiety and satiations to a preload in normal weight, boys.

the effect of exercise (exr) on short-term food intake (fi) and subjective appetite was investigated in normal weight (nw), boys were randomized into 4 treatments. each boy consumed either a non-caloric sweetened control (con) or glu drink after either exercise (exr) or sedentary activity. subjects exercised at 25% above their ventilation threshold (vet).

Eligibility criteria:
inclusion criteria: * healthy boys with no emotional, behavioral or learning problems exclusion criteria: * girls

Keywords: girls
study for rural innovations in the delivery of exercise

Conditions: Knee Osteoarthritis

Summary: : falls are the primary cause of injury and a leading cause of disability and mortality among older adults. risk factors for falling are common among older adults with knee osteoarthritis (oa) - a highly prevalent condition. physical exercise is consistently the most efficacious intervention for preventing falls in older adults. however, access to these programs is severely limited in rural settings. considering that rural communities have a higher disease burden and higher proportion of older adults than non-rural areas, there is a critical need to (1) adapt evidence-based exercise programs for remote delivery to increase access for rural older adults and (2) develop pathways to implement exercise programs in rural health care systems that consistently reach and engage patients with knee oa. accordingly, the proposed project aims to refine a protocol for remote delivery of enhance fitness (ef). ef is an evidence-based, group exercise program involving strength, endurance, and balance training that is recommended for falls prevention and oa management


Eligibility criteria:
inclusion criteria: * community-dwelling * english-speaking * physician diagnosed knee osteoarthritis * knee pain that occurs almost daily for at least the past 3 months and is moderate to severe in intensity * knee pain-related difficulty with walking or climbing stairs * resident of a rural county exclusion criteria: * cognitive impairment determined by a mini montreal cognitive assessment score of \<11 * any of the following in the past 6 months: cancer requiring treatment (except for non- melanoma skin cancer), heart attack, stroke, hip fracture, hip/knee replacement, spinal surgery, heart surgery, deep vein thrombosis, or pulmonary embolus; and temporary exclusions * hospitalization within the last month * ≥3 falls within the past month

Keywords: physical activity rural older adults
folfiri versus irinotecan as second-line treatment in metastatic colorectal cancer patients

Conditions: Colorectal Carcinoma

Summary: this study is designed to compare the efficacy and safety of folfiri regimen with irinotecan monodrug in the treatment of advanced colorectal cancer patients in the second-line setting.


Eligibility criteria:
inclusion criteria: * aged 18-70 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma * eastern cooperative oncology group performance status of 0 to 2 * life expectancy of ≥ 3 months * patients who had failed first-line treatment with either xelox (capecitabine combined with oxaliplatin) or folfox (5-fluorouracil/leucovorin with oxaliplatin) * at least one measurable disease lesion according to the response evaluation criteria in solid tumors (recist 1.1) criteria * have adequate bone marrow, hepatic, and renal function exclusion criteria: * patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction * patients with symptomatic brain metastases * active clinical severe infection * previously received irinotecan * dihydropyrimidine dehydrogenase (dpd) enzyme adequate
efficacy and safety of lucentis for clinically significant macular edema secondary to central retinal vein occlusion

Conditions: Retinal Vein Occlusion; Macular Edema

Summary: this study aims to assess if lucentis injection applied into the eye is superior to conventional treatment concerning the prevention of visual loss in patients having clinically significant macular edema secondary to retinal vein occlusion


Eligibility criteria:
inclusion criteria: * macular edema persisting for more than 3 months period despite conventional medication. * central retinal vein occlusion is confirmed by slit-lamp biomicroscopy and fluorescein angiography (flag). * patients randomized into ranibizumab-treated group do not receive macular laser treatment. * macular edema is defined by oct: the thickness of central foveal area calculated by macular map analysis is above 280 μm and/or retinal thickness is above 330 μm at any region of the macula calculated by retinal thickness analysis. * baseline visual acuity is less than 64 etdrs letters (or 0.4 decimal equivalent). exclusion criteria: * diabetes mellitus * additional vitreoretinal diseases * history of pars plana vitrectomy * previous macular grid laser treatment * intravitreal triamcinolone acetonid treatment * complicated cataract surgery * advanced glaucomatous damage of optic nerve head * cataract (except mild, defined as grade 1 nuclear sclerosis and/or grade 1 posterior subcapsular cataract) * age-related macular degeneration * pregnancy and lactation * women in childbearing potential who are not using double safe contraception

Keywords: macular edema secondary to retinal vein occlusion
high dose chop in lymphoma

Conditions: Non-Hodgkin's Lymphoma

Summary: the study hypothesis is that intensification of chop by dose escalation of the most active drugs in the combination will improve treatment outcome. patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing chop. the planned dose is 3000 mg/m2 which is 4 times the atandard one. only 4 cycles are given.


Eligibility criteria:
inclusion criteria: * large-cell non-hodgkin's lymphoma * ipi low-intermediate, high-intermediate and high or bulky mediastinum * age 18-65 exclusion criteria: * previous treatment for lymphoma * serious concurrent systemic disease

Keywords: large cell lymphoma chop cyclophosphamide high-dose
162 mg of aspirin for prevention of preeclampsia

Conditions: Preeclampsia

Summary: this is a study to assess if 162 mg of aspirin will decrease rates of preeclampsia in pregnant patients compared to 81 mg of aspirin.

after screening to meet inclusion criteria, pregnant patients at the family medicine clinic will be asked to take 162 mg aspirin daily for 6 months, starting at about 12 weeks gestation and continued until the end of pregnancy. they will be monitored every 4 weeks until week 28, then every 2 weeks until week 36, and then weekly from week 36 on. participants will be screened at these visits for medication compliance (taking, missed doses, side effects, etc). patients will be subject to lab work as is routinely indicated for preeclampsia. at the end of the study period, accumulated study data will be compared with historical data from the family medicine clinic on rates of preeclampsia and outcomes in patients taking 81 mg for preeclampsia prevention.

Eligibility criteria:
inclusion criteria: * any pregnant patient at peoria fmc * hx of pre-eclampsia * multifetal gestation * chronic hypertension * type 1 or 2 diabetes * autoimmune disease * renal disease * nulliparity * obesity * family hx of pre-eclampsia * sociodemographic characteristics * age \>= 35 years of age * personal history factors (lbw, sga, \> 10-year pregnancy interval, adverse pregnancy outcomes exclusion criteria: * at high risk of side effects from asa therapy * hx of hemorrhagic stroke * hx of gi bleed, g6pd * liver disease * nsaid or salicylate allergy) * patients confirmed to be not compliant with therapy
efficacy and safety of pimecrolimus cream 1% in patients (2 to 11 years old) with mild to moderate facial atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this study is not being conducted in the united states of america (usa). atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching). the active ingredient of pimecrolimus inhibits t-cell activation. these cells are involved in the inflammatory component of the disease. this study will test the safety and efficacy of pimecrolimus cream 1% in atopic dermatitis of the face in patients intolerant of, or dependent on, topical corticosteroids.


Eligibility criteria:
inclusion criteria: * mild to moderate facial atopic dermatitis * patients intolerant of, or dependent on, topical corticosteroids exclusion criteria: * concurrent skin diseases (infections) * immunocompromised * recently received phototherapy or systemic therapy

Keywords: atopic dermatitis t-cell pimecrolimus children facial facial atopic dermatitis
postoperative delirium in the post-anesthesia care unit

Conditions: Delirium, Postoperative

Summary: this study aims to investigate the incidence of postoperative delirium (pod) in the pacu and analyze its influencing factors, in order to provide theoretical basis for early screening and intervention for high-risk pod population. blood samples of some study subjects will be collected and analyzed using molecular detection methods to provide a basis and insights into the pathophysiological mechanisms of pod.

study design type: multi-center, observational, case-control study based on propensity score matching. the leading unit is tongji hospital, tongji medical college, huazhong university of science and technology, and the participating unit is the first hospital of harbin medical university. record general clinical information, surgical-anesthesia-related information, recovery indicators, pain status, adverse events in pacu, and occurrences of postoperative delirium of all study subjects meeting the inclusion criteria of this study. based on the occurrence of postoperative delirium, the subjects will be divided into delirium group and non-delirium group for univariate analysis. univariate factors with statistical significance will be included in a multiple logistic regression analysis to further identify risk factors for postoperative delirium. some selected factors can undergo roc curve analysis to calculate the optimal cutoff value. due to the limited number of subjects experiencing postoperative delirium, propensity score matching will be used to improve the statistical efficiency for analysis of risk factors for postoperative delirium. furthermore, for patients with postoperative delirium, a small amount of blood samples will be collected by the researchers for analysis of inflammatory factors and other components.

Eligibility criteria:
inclusion criteria: 1. patients voluntarily participating in this study 2. age ≥18 years old 3. asa classification i-iv 4. complete clinical data exclusion criteria: 1. asa classification v and above 2. history of severe central nervous system diseases, psychiatric disorders, cognitive impairment, intellectual disability, or mini-mental state examination (mmse) score ≤23 3. patients with communication barriers 4. patients with missing clinical data 5. patients with severe complications during pacu observation requiring reintubation, reoperation, or transfer to the intensive care unit for further treatment
aurora test for patients treated with recombinant gonadotropins

Conditions: Infertility

Summary: this is an observational study. the main aim is to determine the expression of potential biomarker genes in the cumulus cells isolated from individual oocytes in two patient cohorts: recombinant human follicle stimulating hormone(hfsh) and recombinant hfsh:human luteinizing hormone(r-hlh) ratio 2:1. algorithms from gene combinations will be identified that predict embryo quality and pregnancy outcomes.


Eligibility criteria:
inclusion criteria: * patients are between 22-38 years old * bmi between 17-33 * provide written informed consent * patients undergoing a first or second icsi treatment cycle. * patients will be treated by icsi (intracytoplasmic sperm injection) * patients agree that the oocytes will be denuded for cumulus testing and agree to the single blastocyst transfer. * patients must be predicted good ovarian responders (amh 1-4,7 ng/ml) with 7-18 follicles of minimum 10-11 mm on trigger day (oocyte retrieval minus 2 days (or -2)) by ultrasound following ovarian stimulation with r-hfsh or r-hfsh with r-hlh in a gonadotropin-releasing hormone (gnrh) antagonist protocol (starting dose recombinant follicle stimulating hormone (rfsh) between 150-225 iu) * hcg trigger after stimulation (r-hcg) exclusion criteria: * women with less than 7 or more than 18 follicles at day -2 or -3 measured by ultrasound * women with history of poor oocyte maturation or known maturation defect * irregular menstrual cycle (\ 35 days) * bmi \ 33 * smoking \> 10 cigarettes per day. * known low ovarian response based on bologna criteria * combined use of urinary and recombinant gonadotropins in the current cycle * patients with severe endometriosis ≥ iii (afs classification) * polycystic ovary syndrome (pcos), defined by revised criteria american society for reproductive medicine (asrm) european society of human reproduction and embryology (eshre) 2018 * patient included in any other study * patient scheduled for preimplantation genetic testing (pgt) * testicular sperm extraction (tese) or extreme oligo-astheno-teratozoospermia (oat) with sperm count below 100.000/ml.
effect of an-pep enzyme on gluten digestion in gluten sensitive individuals

Conditions: Non-coeliac Gluten Sensitivity

Summary: in this trial, the effect of a low and a high dose an-pep will be investigated in gluten sensitive individuals. volunteers receive a breakfast with background (0.5 g) gluten. capsules are taken in the morning within 5 min after start of breakfast. gastrointestinal fluid will be sampled over 3 hours to measure gluten degradation. after 5 volunteers have completed 3 test days, a blind interim analysis is performed by a third party based on which it is decided whether to proceed with the low an-pep dose.


Eligibility criteria:
inclusion criteria: * male/female * age ≥18 but \<70 yr * females: hormonal contraceptive treatment * self-reported gluten-sensitive individuals fulfilling the rome iii criteria while consuming gluten * subject has read and understood the information provided on the study and given written informed consent exclusion criteria: * coeliac disease serology while consuming gluten (serological test for tissue transglutaminase iga antibodies and total iga antibodies) * wheat allergy (serological test for wheat protein ige antibodies) * medication or medical condition that affects gastric emptying or secretion * females: pregnancy or breast-feeding * inability to swallow the gastroduodenal feeding tube * any medical condition that in the opinion of the investigators may interfere with the study and may jeopardise the health status of the participant * any condition that in the opinion of the investigators may interfere with the study and may jeopardise the health status of the participant

Keywords: enzyme gluten food intolerance
ev-aifib preliminary evaluation of the aifib software

Conditions: Software Performance Evaluation a Posteriori

Summary: to evaluate the intraoperative effectiveness of the aifib software in real time in the detection of atrial fibrillation drivers during an ablation procedure.


Eligibility criteria:
inclusion criteria: * patients 18 years of age or older * etiology in the following list: * atrial fibrillation for which a conventional anatomical approach alone (pulmonary vein isolation) is not performed: persistent af, long standing persistent af paroxysmal af (redo), paroxysmal af * atrial tachycardia de novo or secondary to af ablation. exclusion criteria: * contraindication to af ablation * major bleeding disorder